NCT04509791View on ClinicalTrials.gov

MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

December 16, 2024

Study Completion Date

December 16, 2024

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Anti-Human Thymocyte Immunoglobulin, Rabbit

MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)

Trial Locations (14)

Unknown

Medical University of Graz, Graz

Medical University of Vienna, Vienna

Universitair Ziekenhuis Antwerpen, Antwerp

Universitair ziekenhuis Brussel, Brussels

Universite Libre de Bruxelles, Brussels

Universitaire Ziekenhuizen Leuven, Leuven

Herlev University Hospital, Herlev

Helsinki University Hospital Children and Adolescents, Helsinki

Hannoversche Kinderheilanstalt Auf der Bult, Hannover

IRCCS Ospedale San Raffaele, Milan

University Medical Centre Ljubljana, Ljubljana

Cambridge University Hospitals NHS Trust, Cambridge

The Royal London Hospital - Barts Health NHS Trust, London

OX3 9DU

Oxford University Hospitals NHS Foundation Trust, Oxford

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT04509791 - MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D) | Biotech Hunter | Biotech Hunter